Biotech | August 09, 2021
Novavax and Serum Institute submits Emergency Use Authorisation of vaccine to regulatory agencies in India, Indonesia and the Philippines
Filing for WHO Emergency Use Authorisation this month
Filing for WHO Emergency Use Authorisation this month
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Deal for 100 million doses with additional 100 million through 2023
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
Pfizer and Moderna are also working on vaccines that target the Omicron variant
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
Subscribe To Our Newsletter & Stay Updated
